Alnylam reports dose-dependent huntingtin reductions in Phase 1b brezosiran study

Alnylam says its Phase 1b brezosiran study showed dose-dependent CSF mutant huntingtin reductions, up to 83% individually, with no dose-dependent safety signals. A pivotal study is planned for 2027 pending regulatory alignment.

Detected & updated continuously · Source: Nebula